Immune checkpoint inhibitor

Open Access
Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies
MIOKO MATSUO, KAZUKI HASHIMOTO, RYUNOSUKE KOGO, RINA JIROMARU, TAKAHIRO HONGO, TOMOMI MANAKO and TAKASHI NAKAGAWA

In Vivo September 2023, 37 (5) 2147-2154; DOI: https://doi.org/10.21873/invivo.13312
Open Access
Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
TOMOMI MANAKO, RYUJI YASUMATSU, TAKAFUMI NAKANO, MIOKO MATSUO, TORANOSHIN TAKEUCHI, MASAHIKO TAURA, AKIHIRO TAMAE, MORIYASU YAMAUCHI, MUNEYUKI MASUDA, KENICHI TAGUCHI and TAKASHI NAKAGAWA

In Vivo March 2023, 37 (2) 747-755; DOI: https://doi.org/10.21873/invivo.13137
Open Access
Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial
YANG-CHENG LEE, WEN-TSUNG HUANG, MING-YANG LEE, CHAO-JUNG TSAO and YIN-HSUN FENG

In Vivo January 2023, 37 (1) 454-460; DOI: https://doi.org/10.21873/invivo.13099
Open Access
Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer
YUKO KUMAGAI, YURIE FUTOH, HIDEYO MIYATO, HIDEYUKI OHZAWA, HIRONORI YAMAGUCHI, SHIN SAITO, KENTARO KURASHINA, YOSHINORI HOSOYA, ALAN KAWARAI LEFOR, NAOHIRO SATA and JOJI KITAYAMA

In Vivo May 2022, 36 (3) 1126-1135; DOI: https://doi.org/10.21873/invivo.12811
You have access
Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi
KAZUHIKO YOSHIDA, KEISUKE HATA, JUNPEI IIZUKA, TSUNENORI KONDO, HIROKI ISHIHARA, HIDEKI ISHIDA, YOJI NAGASHIMA, KAZUNARI TANABE and TOSHIO TAKAGI

In Vivo March 2022, 36 (2) 1030-1034; DOI: https://doi.org/10.21873/invivo.12798
You have access
Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency
KOKI KATO, TOMOHIRO MIZUNO, TAKENAO KOSEKI, YOSHIMASA ITO, MASAKAZU HATANO, KAZUO TAKAHASHI, SHIGEKI YAMADA and NAOTAKE TSUBOI

In Vivo September 2021, 35 (5) 2831-2840; DOI: https://doi.org/10.21873/invivo.12570
You have access
Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma
MAKI YOSHINO, HIROKI ISHIHARA, YUDAI ISHIYAMA, HIDEKAZU TACHIBANA, DAISUKE TOKI, KAORI YAMASHITA, HIROHITO KOBAYASHI, HIRONORI FUKUDA, KAZUHIKO YOSHIDA, TOSHIO TAKAGI, JUNPEI IIZUKA, HIDEKI ISHIDA, TSUNENORI KONDO and KAZUNARI TANABE

In Vivo September 2021, 35 (5) 2855-2862; DOI: https://doi.org/10.21873/invivo.12573
You have access
Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors
KANA HAYASHI, KOTARO TOKUI, MINEHIKO INOMATA, KENJI AZECHI, ISAMI MIZUSHIMA, NAOKI TAKATA, CHIHIRO TAKA, SEISUKE OKAZAWA, KENTA KAMBARA, SHINGO IMANISHI, TOSHIRO MIWA, RYUJI HAYASHI, SHOKO MATSUI, SATOSHI NOMURA and KAZUYUKI TOBE

In Vivo May 2021, 35 (3) 1687-1692; DOI: https://doi.org/10.21873/invivo.12428
You have access
Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer
YASUYOSHI SATO, NAOKI FUKUDA, YU FUJIWARA, XIAOFEI WANG, TETSUYA URASAKI, AKIHIRO OHMOTO, KENJI NAKANO, MAKIKO ONO, JUNICHI TOMOMATSU, HIROKI MITANI and SHUNJI TAKAHASHI

In Vivo March 2021, 35 (2) 1211-1215; DOI: https://doi.org/10.21873/invivo.12371
You have access
Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung
SHINICHIRO OKAUCHI, YUIKA SASATANI, TOSHIHIRO SHIOZAWA, HIDEYASU YAMADA, KUNIHIKO MIYAZAKI, NORIO TAKAYASHIKI and HIROAKI SATOH

In Vivo May 2020, 34 (3) 1439-1443; DOI: https://doi.org/10.21873/invivo.11926

Main menu

User menu

Search

Immune checkpoint inhibitor

Pages